Cabazitaxel Dihydrate is a semi-synthetic taxane derivative and microtubule inhibitor indicated for the treatment of metastatic castration-resistant prostate cancer in patients previously treated with… Read more
Cabazitaxel Dihydrate is a semi-synthetic taxane derivative and microtubule inhibitor indicated for the treatment of metastatic castration-resistant prostate cancer in patients previously treated with chemotherapy. By binding to tubulin and inhibiting its polymerization, this agent disrupts cell division, making it a critical therapy in oncology. Accurate analytical characterization of this compound during manufacturing and quality control requires precise reference standards. This category includes high-quality Cabazitaxel Dihydrate reference standards, alongside its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled analogs. These compounds are essential for impurity profiling, method validation, and quantitative analysis, enabling pharmaceutical laboratories to ensure the safety, potency, and purity of drug products throughout the development and production lifecycle.